UBS Asset Management Americas Inc. increased its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 88.9% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 26,236 shares of the biopharmaceutical company’s stock after buying an additional 12,345 shares during the period. UBS Asset Management Americas Inc. owned about 0.06% of Agios Pharmaceuticals worth $1,532,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $8,246,000. State Street Corp raised its stake in shares of Agios Pharmaceuticals by 13.8% in the fourth quarter. State Street Corp now owns 1,240,585 shares of the biopharmaceutical company’s stock worth $51,772,000 after buying an additional 150,244 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Agios Pharmaceuticals by 17.8% in the first quarter. First Trust Advisors LP now owns 639,579 shares of the biopharmaceutical company’s stock worth $37,351,000 after buying an additional 96,712 shares during the last quarter. Capital Fund Management S.A. acquired a new stake in shares of Agios Pharmaceuticals during the first quarter worth about $5,150,000. Finally, Wells Fargo & Company MN raised its stake in shares of Agios Pharmaceuticals by 312.0% in the first quarter. Wells Fargo & Company MN now owns 40,084 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 30,354 shares during the last quarter. Institutional investors own 84.53% of the company’s stock.

Shares of Agios Pharmaceuticals Inc (NASDAQ AGIO) traded down 0.65% during trading on Monday, hitting $61.06. The stock had a trading volume of 635,908 shares. The stock’s 50-day moving average price is $55.14 and its 200 day moving average price is $50.99. Agios Pharmaceuticals Inc has a one year low of $35.84 and a one year high of $67.74. The stock’s market cap is $2.94 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.56) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.24. The business had revenue of $10.51 million during the quarter, compared to the consensus estimate of $9.65 million. Agios Pharmaceuticals had a negative net margin of 629.67% and a negative return on equity of 79.70%. Agios Pharmaceuticals’s revenue was down 66.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.64) EPS. On average, equities analysts forecast that Agios Pharmaceuticals Inc will post ($6.43) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals Inc (NASDAQ:AGIO) Shares Bought by UBS Asset Management Americas Inc.” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/07/ubs-asset-management-americas-inc-purchases-12345-shares-of-agios-pharmaceuticals-inc-nasdaqagio-updated-updated-updated.html.

A number of analysts have recently issued reports on AGIO shares. Oppenheimer Holdings, Inc. set a $75.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 1st. Cann reaffirmed a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, April 19th. Zacks Investment Research lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 18th. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Finally, Janney Montgomery Scott lowered Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 26th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $67.25.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,036 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $47.10, for a total value of $95,895.60. Following the completion of the sale, the director now owns 91,206 shares of the company’s stock, valued at approximately $4,295,802.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $50.02, for a total transaction of $150,060.00. Following the completion of the sale, the chief executive officer now directly owns 1,100 shares of the company’s stock, valued at approximately $55,022. The disclosure for this sale can be found here. Insiders have sold a total of 79,120 shares of company stock valued at $4,557,207 in the last ninety days. 10.55% of the stock is currently owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.